Special Issue "Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".

Deadline for manuscript submissions: 25 June 2021.

Special Issue Editor

Charles A Kunos, MD PhD
Website
Guest Editor
National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Medical Officer and Coordinator, Investigational Therapeutics & Radiation
Interests: radiopharmaceuticals; radiotherapy; gynecological cancer

Special Issue Information

Dear Colleagues,

An overarching aspect for the radiopharmaceutical drug development effort is patient and provider education through use of academic white papers on key topics. The Journal Pharmaceuticals has offered us the opportunity to write academic white papers for a Special Issue on “Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers.” The focus of this effort is to introduce and to describe the United States National Cancer Institutes and the academic or pharmaceutical collaborator development of these agents. Topics might range from radiopharmaceutical combination with early-phase investigational agents that test tolerability and early signs of efficacy or social aspects of this type of research, such as financial toxicity.

Some of the initial topics discussed by the NCI are found at this link to serve as a topic guide:

https://ctep.cancer.gov/investigatorResources/radiopharmaceutical_development_initiative.htm

Please email me at [email protected] to discuss your planned topic so that there is not significant overlap in contributed material.

Charles A Kunos, MD PhD
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • radiopharmaceuticals
  • radiotherapy
  • ovarian cancer
  • stereotactic
  • financial toxicity

Related Special Issues

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Other

Open AccessOpinion
Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma
Pharmaceuticals 2020, 13(10), 287; https://doi.org/10.3390/ph13100287 - 30 Sep 2020
Viewed by 450
Abstract
Switch maintenance, or using alternative therapeutic agents that were not administered during a prior course of cancer treatment, has emerged as an active clinical research and regulatory agency-approvable path in the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) drug-development sequence. To [...] Read more.
Switch maintenance, or using alternative therapeutic agents that were not administered during a prior course of cancer treatment, has emerged as an active clinical research and regulatory agency-approvable path in the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) drug-development sequence. To better inform the design of therapeutic radiopharmaceutical trials, we reviewed academic scholarship discussing the clinical use of maintenance approaches to cancer treatment. Women with advanced-stage primary platinum-refractory or platinum-resistant ovarian carcinoma and their courses of treatment provide context for our discussion. Twenty-four (10%) out of 244 trials for women with ovarian carcinoma fit our search terms for maintenance trials. Five (2%) trials studied radiopharmaceuticals as switch maintenance. In our opinion, radiopharmaceutical switch maintenance merits further testing in prospective trials for women with advanced-stage primary platinum recurrent or refractory ovarian carcinoma. Full article
(This article belongs to the Special Issue Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers)
Show Figures

Figure 1

Open AccessOpinion
Financial Toxicity Encountered in Therapeutic Radiopharmaceutical Clinical Development for Ovarian Cancer
Pharmaceuticals 2020, 13(8), 181; https://doi.org/10.3390/ph13080181 - 05 Aug 2020
Cited by 1 | Viewed by 760
Abstract
Financial toxicity or the debt a cancer survivor incurs from the costs of their medical cancer care is an understudied aspect in the clinical development of experimental therapeutic agents. The United States National Cancer Institute (NCI) Cancer Therapy Evaluation Program studies experimental therapeutic [...] Read more.
Financial toxicity or the debt a cancer survivor incurs from the costs of their medical cancer care is an understudied aspect in the clinical development of experimental therapeutic agents. The United States National Cancer Institute (NCI) Cancer Therapy Evaluation Program studies experimental therapeutic agents like radiopharmaceuticals in both early and late phase trials, which provide opportunities to comprehend more clearly the possible sources of financial toxicity incurred by cancer survivors. We reviewed the academic scholarship describing fiscal and social costs involved in the development of therapeutic radiopharmaceuticals. Because many ovarian cancer survivors outlive their disease through initial and, perhaps, multiple treatment courses, these women and their treatments provide context for our discussion on financial toxicity. 16 (27%) of 60 articles discuss financial toxicity incurred by women with ovarian cancer; none described financial toxicity associated with regulatory agency-approved or experimental therapeutic radiopharmaceuticals. Fiscal costs of radiopharmaceutical dose and schedule and social costs of individual productivity loss or asset expenditure arose as primary financial toxicities. The development of radiopharmaceuticals for women with ovarian cancer remains a high priority for the NCI Cancer Therapy Evaluation Program. Weighing radiopharmaceutical clinical benefit against measures of financial toxicity is challenging and warrants further study in prospective radiopharmaceutical clinical trials. Full article
(This article belongs to the Special Issue Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers)
Back to TopTop